AR042192A1 - Derivados antivirales de nucleosidos de pirimidina - Google Patents

Derivados antivirales de nucleosidos de pirimidina

Info

Publication number
AR042192A1
AR042192A1 ARP030104225A ARP030104225A AR042192A1 AR 042192 A1 AR042192 A1 AR 042192A1 AR P030104225 A ARP030104225 A AR P030104225A AR P030104225 A ARP030104225 A AR P030104225A AR 042192 A1 AR042192 A1 AR 042192A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
unbranched
branched
hydrogen
Prior art date
Application number
ARP030104225A
Other languages
English (en)
Inventor
Joseph Armstrong Martin
Keshab Sarma
Mark Smith
Dennis G Smith
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32329161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR042192(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR042192A1 publication Critical patent/AR042192A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a los derivados de nucleósidos para el tratamiento de las infecciones de la Hepatitis C viral incluyendo compuestos de la fórmula (1), composiciones farmacéuticas que comprenden estos compuestos y métodos para el tratamiento o profilaxis de enfermedades mediadas por el Virus de la Hepatitis C que emplean dichos compuestos en monoterapia o en terapia de combinación. También se suministra un proceso para la preparación de un nucleósido de pirimidina 1', 3', 4'- triacilo de un nucleósido N, 1', 3', 4'- tetraacilpirimidina. Reivindicación 1: Un compuesto de la fórmula (1) en donde: R1 y R2 se seleccionan independientemente del grupo que consiste en hidrógeno, COR5, C(=O)OR5, C(=O)SR5, C(=O)NHR5 y COCH(R6)NHR7; R3 y R4 se selecciona independientemente del grupo que consiste en hidrógeno COR5, C(=O)OR5, C(=O)SR5 y COCH(R6)NHR7, o R3 y R4 tomados juntos se seleccionan del grupo que consiste en CH2, C(CH3)2 y CHPh; R5 se selecciona independientemente del grupo que consiste en alquilo C1-18 no ramificado o ramificado, alquenilo C1-18 no ramificado o ramificado, alquinilo C1-18 no ramificado o ramificado, haloalquilo C1-18 inferior, cicloalquilo C3-8, alquilo sustituido por cicloalquilo C3-8, fenilo opcionalmente independientemente sustituido con uno de los tres sustituyentes seleccionados del grupo que consiste en halo, alquilo inferior, alcoxi inferior, tioalquilo inferior, sulfinil alquilo inferior, sulfonil alquilo inferior, nitro, y ciano, CH2Ph en donde en el anillo fenilo se sustituye opcionalmente como se describió anteriormente y CH2OPh en donde en el anillo fenilo se sustituye opcionalmente como se describió anteriormente; R6 se selecciona independientemente del grupo que consiste en las cadenas laterales de aminoácidos que se dan de forma natural y alquilo C1-5 no ramificado o ramificado; y R7 se selecciona del grupo que consiste en hidrógeno, R5OCO; o, R6 y R7 juntos son (CH2)3; y hidratos, solvatos, claratos y sales de adición ácida de las mismas; con la condición de que al menos uno de R1, R2, R3 o R4 es otro que hidrógeno.
ARP030104225A 2002-11-19 2003-11-17 Derivados antivirales de nucleosidos de pirimidina AR042192A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42744702P 2002-11-19 2002-11-19
US48397003P 2003-07-01 2003-07-01

Publications (1)

Publication Number Publication Date
AR042192A1 true AR042192A1 (es) 2005-06-15

Family

ID=32329161

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104225A AR042192A1 (es) 2002-11-19 2003-11-17 Derivados antivirales de nucleosidos de pirimidina

Country Status (29)

Country Link
US (1) US6846810B2 (es)
EP (1) EP1565481B1 (es)
JP (1) JP4362450B2 (es)
KR (1) KR100676662B1 (es)
AR (1) AR042192A1 (es)
AT (1) ATE335755T1 (es)
AU (1) AU2003288064B2 (es)
BR (1) BR0316407A (es)
CA (1) CA2504846C (es)
CO (1) CO5550501A2 (es)
CY (1) CY1106207T1 (es)
DE (1) DE60307503T2 (es)
DK (1) DK1565481T3 (es)
ES (1) ES2270136T3 (es)
HR (1) HRP20050417B1 (es)
IL (1) IL168266A (es)
JO (1) JO2403B1 (es)
MX (1) MXPA05005282A (es)
MY (1) MY136229A (es)
NO (1) NO330424B1 (es)
NZ (1) NZ539644A (es)
PA (1) PA8588501A1 (es)
PE (1) PE20040836A1 (es)
PL (1) PL210967B1 (es)
PT (1) PT1565481E (es)
RU (1) RU2327701C2 (es)
TW (1) TWI332507B (es)
UY (1) UY28084A1 (es)
WO (1) WO2004046159A1 (es)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) * 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
ATE407674T1 (de) * 2002-04-09 2008-09-15 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
MXPA04012802A (es) * 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
MXPA05005192A (es) * 2002-11-15 2005-09-08 Idenix Cayman Ltd Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
CA2509687C (en) * 2002-12-12 2012-08-14 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
CA2511616A1 (en) * 2002-12-23 2004-07-15 Idenix (Cayman) Limited Process for the production of 3'-nucleoside prodrugs
DE602004003389T2 (de) * 2003-06-19 2007-09-13 F. Hoffmann-La Roche Ag Verfahren zur herstellung von 4'-azidonukleosidderivaten
WO2006000922A2 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
EP1794172B1 (en) * 2004-08-23 2009-07-15 F.Hoffmann-La Roche Ag Antiviral 4'-azido-nucleosides
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US20070166378A1 (en) * 2005-06-09 2007-07-19 Flamel Technologies, Inc. Oral ribavirin pharmaceutical compositions
JP2009504704A (ja) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート
BRPI0616385A2 (pt) * 2005-09-22 2011-06-21 Hoffmann La Roche o-acilação seletiva de nucleosìdeos
RU2422454C2 (ru) * 2005-12-09 2011-06-27 Ф. Хоффманн-Ля Рош Аг Антивирусные нуклеозиды
ES2350497T3 (es) * 2005-12-14 2011-01-24 F. Hoffmann-La Roche Ag Formulación de profármacos para el vhc.
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
ES2422290T3 (es) * 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
WO2007113159A1 (en) 2006-04-04 2007-10-11 F. Hoffmann-La Roche Ag 3',5'-di-o-acylated nucleosides for hcv treatment
BRPI0719174A2 (pt) * 2006-10-10 2017-06-13 Hoffmann La Roche preparação de pirimidinas ribofuranosil nucleosídeos
AU2007306405A1 (en) 2006-10-10 2008-04-17 Medivir Ab HCV nucleoside inhibitor
US8501933B2 (en) 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
CN101528717B (zh) 2006-11-09 2013-04-24 弗·哈夫曼-拉罗切有限公司 噻唑和*唑-取代的芳基酰胺类化合物
ATE478084T1 (de) * 2006-12-11 2010-09-15 Hoffmann La Roche Verfahren zur herstellung von 4'- azidocytidinderivaten
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
BRPI0808089A2 (pt) 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
EP2142178B1 (en) * 2007-03-29 2012-01-11 F. Hoffmann-La Roche AG Pharmaceutical composition and process
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CL2008003511A1 (es) * 2007-11-29 2010-02-19 Metabasis Therapeutics Inc Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
AU2008337660B2 (en) * 2007-12-17 2014-02-06 F. Hoffmann-La Roche Ag Triazole-substituted arylamide derivatives and their use as P2X3 and /or P2X2/3 purinergic receptor antagonists
JP5301561B2 (ja) * 2007-12-17 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー 新規なピラゾール置換アリールアミド
WO2009077365A1 (en) 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazole-substituted arylamides
EP2570407B1 (en) * 2007-12-17 2014-08-13 F. Hoffmann-La Roche AG Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
JP2011526893A (ja) * 2008-07-02 2011-10-20 イデニク プハルマセウティカルス，インコーポレイテッド ウイルス感染の治療のための化合物、及び医薬組成物
EP2315802A4 (en) * 2008-07-31 2012-04-18 3M Innovative Properties Co AZIUM COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
CA2745284A1 (en) * 2008-12-18 2010-06-24 F. Hoffmann-La Roche Ag Biomarkers for hcv treatment response
TW201031675A (en) * 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2389164B1 (en) * 2009-01-21 2014-08-13 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising a hcv polymerase inhibitor prodrug
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
JP2012519661A (ja) 2009-03-06 2012-08-30 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
SG177301A1 (en) * 2009-06-22 2012-02-28 Hoffmann La Roche Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists
ES2593405T3 (es) * 2009-06-22 2016-12-09 F. Hoffmann-La Roche Ag Nuevas arilamidas sustituidas por benzoxazolona
CN102574778B (zh) * 2009-06-22 2015-01-07 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
BRPI1011744A2 (pt) 2009-06-24 2016-03-22 Hoffmann La Roche composto antiviral heterocíclico.
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
CN102498100A (zh) 2009-09-21 2012-06-13 弗·哈夫曼-拉罗切有限公司 抗病毒杂环化合物
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
CA2778206A1 (en) 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ600608A (en) 2009-12-18 2015-01-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
PL2528930T3 (pl) * 2010-01-28 2014-03-31 Riboscience Llc 4`-azydonukleozydy jako związki przeciw hcv
HUE026235T2 (en) 2010-03-31 2016-06-28 Gilead Pharmasset Llc Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CN102917585A (zh) 2010-04-01 2013-02-06 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US8877731B2 (en) 2010-09-22 2014-11-04 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
EP2755985B1 (en) 2011-09-12 2017-11-01 Idenix Pharmaceuticals LLC Compounds and pharmaceutical compositions for the treatment of viral infections
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
WO2013133927A1 (en) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AU2013329521B2 (en) 2012-10-08 2018-04-19 Centre National De La Recherche Scientifique 2'-chloro nucleoside analogs for HCV infection
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
EP2920195A1 (en) 2012-11-14 2015-09-23 IDENIX Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10683321B2 (en) 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
SG11201702430WA (en) 2014-09-26 2017-04-27 Riboscience Llc 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EP3737676B1 (en) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
EP4157272A1 (en) 2020-05-29 2023-04-05 Gilead Sciences, Inc. Remdesivir treatment methods
MX2022016405A (es) 2020-06-24 2023-01-30 Gilead Sciences Inc Análogos de nucleósido de 1¿-ciano y usos de estos.
WO2022008025A1 (en) * 2020-07-05 2022-01-13 Since & Technology Development Fund Authority 2-hydroxyiminopyrimidine nucleosides and derivitives and antiviral uses thereto
JP2023540225A (ja) 2020-08-27 2023-09-22 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998807A (en) 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
SE8801729D0 (sv) 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
US5449664A (en) * 1988-11-21 1995-09-12 Syntex (U.S.A.) Inc. Antiviral agents
EP0375329B1 (en) 1988-12-19 1995-05-31 The Wellcome Foundation Limited Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
DE4207363A1 (de) * 1992-03-04 1993-09-09 Max Delbrueck Centrum Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
DE4311801A1 (de) 1993-04-09 1994-10-13 Hoechst Ag Neue Carbonsäureester von 2-Amino-7-(1,3-dihydroxy-2-propoxymethyl)purin, deren Herstellung sowie deren Verwendung
US6184376B1 (en) 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
PL347268A1 (en) 1998-10-16 2002-03-25 Schering Corp Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
EP1244356A4 (en) 1999-12-23 2003-03-19 Icn Pharmaceuticals COMPOSITIONS AND METHODS RELATING TO NUCLEOSIDES-L, NUCLEOTIDES-L AND THEIR ANALOGS
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives

Also Published As

Publication number Publication date
JP2006519169A (ja) 2006-08-24
RU2327701C2 (ru) 2008-06-27
CY1106207T1 (el) 2011-06-08
DE60307503D1 (de) 2006-09-21
PE20040836A1 (es) 2004-11-25
KR20050083909A (ko) 2005-08-26
PA8588501A1 (es) 2004-05-26
NO20052304L (no) 2005-06-23
RU2005119633A (ru) 2006-01-27
US20040121980A1 (en) 2004-06-24
HRP20050417B1 (hr) 2013-11-08
AU2003288064A1 (en) 2004-06-15
PL210967B1 (pl) 2012-03-30
UY28084A1 (es) 2004-05-31
ES2270136T3 (es) 2007-04-01
NO330424B1 (no) 2011-04-11
PL377632A1 (pl) 2006-02-06
DK1565481T3 (da) 2006-12-18
WO2004046159A1 (en) 2004-06-03
IL168266A (en) 2010-11-30
MXPA05005282A (es) 2005-07-25
BR0316407A (pt) 2005-10-11
EP1565481B1 (en) 2006-08-09
DE60307503T2 (de) 2007-08-16
WO2004046159A8 (en) 2005-06-30
JP4362450B2 (ja) 2009-11-11
MY136229A (en) 2008-08-29
JO2403B1 (en) 2007-06-17
CA2504846C (en) 2012-01-03
AU2003288064B2 (en) 2008-10-09
US6846810B2 (en) 2005-01-25
TWI332507B (en) 2010-11-01
EP1565481A1 (en) 2005-08-24
NZ539644A (en) 2007-01-26
PT1565481E (pt) 2006-12-29
TW200426154A (en) 2004-12-01
HRP20050417A2 (en) 2006-06-30
CA2504846A1 (en) 2004-06-03
ATE335755T1 (de) 2006-09-15
CO5550501A2 (es) 2005-08-31
KR100676662B1 (ko) 2007-02-01

Similar Documents

Publication Publication Date Title
AR042192A1 (es) Derivados antivirales de nucleosidos de pirimidina
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
DK2097434T3 (da) Nukleosidarylphosphoramidater og deres anvendelse som antivirale midler til behandlingen af hepatitis C virus
AR056850A1 (es) MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA
PE20120257A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
ECSP034897A (es) Nucleosidos 4'-sustituidos
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
BR112012015951A2 (pt) 4 azido-nucleosídeos como compostos anti-hcv
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
AR062056A1 (es) Derivados heterociclicos fusionados y metodos de uso
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
PE20070124A1 (es) Derivados de heteroaril para tratar virus
PE20091424A1 (es) Nucleosidos 2',4'-sustituidos como agentes antivirales
ECSP055801A (es) Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
PE20171620A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas
PE20160120A1 (es) Derivados de nucleosido 4'-fluoro-2'-metilo sustituido
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
AR065249A1 (es) Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales.
PE20220252A1 (es) Compuestos de pirrol
PE20011349A1 (es) 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
AR078155A1 (es) Derivados de benzodiazepinas, composiciones farmaceuticas y sus usos
AR042335A1 (es) Derivados de nucleosido antivirales

Legal Events

Date Code Title Description
FC Refusal